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N europeptides released in skin from nerve fib.ers may interact 
with endogenous growth factors (o~ other mlto~emc.agent~) 
to induce psoriasis lesions cha:acten~ed by prohferatmg epI-
dermal keratinocytes. The mltogemc effects of two neuro-
peptides. substance P (SP) and vasoactive intestinal peptide 
(VIP) , on human adult and newborn keratin~cytes were ob-
served in the presence or absence of leukotnene B4 (LTB4) 
and leukotriene C 4 (L TC4). In the presence of SP or VIP. 
L TB4 (but not L TC4) demonstrated substantial increase in 
thymidine incorporation into DNA. which was confirmed 
by cell-growth observations using the hexosarninidase assay. 
In the absence of either neuropeptide. LTB4 had only mar-
ginal effects, especially with adult (but not newborn) kerati-
L eukotrienes playa biologic role in the pathophysiology of many inflammatory skin diseases and of psoriasis in particular p .2]. ~Ie~ate~ concentrations .ofleukotrienes are found m pSOriaSIS lesIOns [3,4]' Applymg leukotriene B. (L TB4) topically to the skin of non-psoriatic patients 
invokes several reactions reminiscent of the disease (erythrema, ac-
cumulation of neutrophils in intraepidermal microabscesses, etc. 
[5]) . Other biologic properties of L TB. may further explain its 
pathogenic sign~ficance i~ psoriasis: i~s potent chemotactic effect on 
neutrophils [6]. Its potential for altering T-cell phenotypes [7], and 
its ability to induce lymphocytes to release cytokines [8]. The fact 
that L TB. is present even in the earliest stages of a psoriatic lesion 
suggests that it plays a fundamental role in precipitating the disease 
[9]. In vivo studies indicate that LTB4 promotes keratinocyte growth 
in guinea pig skin [10]. and an in vitro study with human keratino-
cytes showed a statistically significant mitogenic effect, however 
weak. of L TB. and other leukotrienes [11]. 
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Abbreviations: 
cAMP: cyclic adenosine monophosphate 
EDTA: ethylenediaminetriacetic acid 
3H-TdR: 3H-thymidine 
L TB.: leukotriene B. 
LTC.: leukotriene C. 
PBS: Phosphate-buffered saline 
SFM: Serum-free medium 
SP: substance P 
TCA: trichloroacetic acid 
VIP: vasoactive intestinal peptide 
nocytes. With adult keratinocytes. L TB4 (but not LTC4) 
demonstrated synergy with both SP and VIP. VIP was mito-
genic to keratinocytes at concentrations as low as 10-12 M 
and exhibited a different dose - response curve depending on 
whether adult or newborn keratinocytes were used. The mi-
togenic effects of SP were abrogated by the SP antagonist 
spantide and those of VIP by the VIP antagonist [Ac-Tyrl, 
D-Phe2] growth-hormone-releasing factor (1-29) amide. 
This study suggests that the mitogenic effects of LTB04 , 
which are elevated in psoriatic lesions. may be enhanced by 
the presence of neuropeptides, especially VIP. These effects 
can be reversed by antagonists that may have potential as 
drugs for the disease.] Invest DermatoI100:132-136, 1993 
Neuropeptides may play an important role in skin physiology. 
Vasoactive intestinal peptide (VIP) and substance P (SP) occur in 
skin tissue. Many studies have shown that these two (and others) 
interact with many types of cutaneous cells, although only recently 
have neuropeptides been shown to stimulate the growth of epider-
mal keratinocytes [12.13]. 
These interactions suggest that these neuropeptides figure promi-
nently in the biology of cells found in lesions of skin diseases having 
an inflammatory component. SP-positive nerve fibers occur in un-
usually high numbers in psoriatic skin [14]. Elevated SP levels are 
found in fluid drawn from spontaneous blisters and suction blisters. 
whether raised on eczematous skin or on psoriatic lesions [15], and 
higher levels of VIP occur in biopsies of psoriatic lesions [16]. De-
pletion of neuropeptides by clinical treatment with capsaicin re-
duces the symptoms of psoriasis (17). 
Evidence suggests a cooperative. sometimes synergistic, interac-
tion between neuropeptides and growth factors. Although not usu-
ally regarded as a growth factor. LTB. amplifies VIP-dependent 
cyclic adenosine monophosphate (cAMP) accumulation in the mur-
ine cerebral cortex [18]. Hypothesizing that LTB. may indeed in-
teract in a similar fashion with SP. VIP, or other neuropeptides to 
modulate keratinocyte proliferation. we used newborn and adult 
skin cells to investigate this modulation and attempted to inhibit the 
effects of neuropeptides and L TB4 on keratinocyte proliferation by 
using an antagonist ofSP (span tide) and of VIP ([Ac-Tyrt. o-Phe2]-
growth hormone releasing factor (1- 29) amide). 
MATERIALS AND METHODS 
Materials Sigma (St. Louis. MO): LTB., leukotriene C. (LTC.) . 
in ethanol and methanol solutions. diluted with methanol as re-
quired; trypsin - ethylenediaminetetraacetic acid (EDT A) solution 
(0.25%; 1 roM EDTA); soybean trypsin inhibitor, dissolved in 
water; p-nitrophenyl-N-acetyl-fJ-o-glucosaminide; Triton X-I00. 
Peninsula Laboratories (Belmont. CA): VIP. SP. spantide ([D_Argt, 
0-T rp7.9. Leu II]-SP); and VIP antagonist ([Ac-Tyrt, D_Phe2] 
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growth-hormone - releasing factor (1- 29) amide). Gibco (Grand 
Island, NY): keratinocyte-serum-free medium (SFM) medium, 
gentamycin: ~mersham (Arlington Heig~lts, IL): 3H-thymidine 
(specific actlVlty, 5 CI/mmol). Gelman SCience (Ann Arbor, MI): 
Glass-fiber filters (13 mm). Collaborative Research (Bedford, MA): 
dispase solution. 
Skin Specimens Skin specimens were either foreskins from 
newborns or were excised from non-psoriatic adults undergoing 
facial cosmetic surgery. 
Primary Culture of Newborn Keratinocytes Immediately 
following circumcision, foreskins were placed in 2 ml of RPMI 
containing gentamycin (5 JLg/ml). The tissue was then stored at 
4 0 C and used within 72 h. Foreskins were placed for approximately 
2 h in D-phosphate-buffered saline (PBS) buffer (free of Ca++ and 
Mg++) that conta~ned fungizone. and antibi.otics. Pieces .(1 cm2) 
were placed in a mixture of 50% dlspase solutIOn (25.0 casemolytlc 
U /ml) and 50% Hanks' solution and incubated for 18-24 h at4 0c. 
After this, the epidermal layers were placed in trypsin-EDTA 
(0.25%,1 mM) at 37"C for 20-30 min, with intermittent aspira-
tion to dissociate the cells . Soybean trypsin inhibitor (final concen-
tration 10 mg/ml in PBS) was added. The cells were collected (500 
rpm, 10 min, at room temperature) and seeded into T150 flasks at 
0.5 X 106 cells/rnl in SFM. At confluency (60%-75%, in approxi-
mately 10 days), the cells were detached with trypsin-EDTA and 
passaged. Cells in the first or second passage were seeded into 12-
well plates at 105 cells/well using SFM. 
Primary Culture of Adult Keratinocytes Single-cell suspen-
sions were prepared by trypsin digestion of adult skin, as previously 
described by Liu and Karasek [19], except that cells were cultured in 
SFM. Primary culture and passaging were performed as before. 
Effect ofLeukotrienes and Neuropeptides on Human Kerati-
nocyte Proliferation After reaching 75% confluency, SFM was 
replaced by SFM without additives (basal medium), and the culture 
continued for 2 d, during which time the cells achieved a quiescent 
state, as indicated by a very low level of 3H-thymidine (lH-TdR) 
incorporation. Then the medium was replaced by fresh basal me-
dium supplemented as follows: 
1. One of the following, at final concentrations of 10-12 - 10- 7 M: 
LTB4, LTC4 (these were diluted in methanol whose final con-
centration did not exceed 0.1 % v /v in experimental or control 
wells), SP, or VIP (diluted in saline). 
2. LTB4 (10-9 M) and SP or VIP (10- 12 - 10-7 M). 
3. LTB. (10-9 M) alone or with SP (10-8 M) in the presence or 
absence of spantide (10-8 or 10- 10 M). 
4. LTB. (10-9 M) alone or with VIP (10- 8 M) in the presence or 
absence of VIP antagonist (10- 8 or 10-10 M) . 
After a further 24 h, cellular proliferation was quantified by the 
incorporation oPH-TdR into cells exposed for 4 hat 0.25 JLCi/m!. 
After this 4-h pulse, cells were rinsed once with D-PBS (Ca++, 
Mg++-free), detached with trypsin-EDTA (0.2 ml, 15 min at 
37°C), and treated with 1 ml of 5% trichloroacetic acid (TCA) per 
wei!. The precipitated macromolecules were collected on 13-mm 
glass-fiber filters that were washed extensively with TCA before 
radioactivity was assayed by scintillation counting. 
Proliferation of keratinocytes was verified on several occasions 
using the hexosaminidase assay [20]. These cells were cultured in 
96-well plates (1.5 X 103 cells/well) using either basal medium 
alone or a 1 : 1 mixture of basal and SFM medium. After 2-7 d, the 
cells were treated with the hexosaminidase substrate p-nitrophenyl-
N -acetyl-.8-o-glucosaminide in solution with Triton X-l 00, as de-
scribed previously [20], and, after 4 h at 37"C, absorbance read at 
405 nm using a Biorad enzyme immunoassay reader (model 2550) . 
RESULTS 
Effect of Leukotrienes on lH_ TdR Incorporation With 
newborn keratinocytes, L TB4 increased 3H_ TdR incorporation 
over control by 40% at 10-9 M LTB4 and LTC4 by 35% at 10- 8 M 
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Figure 1. Mitogenic effects of leukotrienes on keratinocytes. Stimulation 
of 3H-TdR into TCA-precipitable material of keratinocytes. Data are ex-
pressed as percentage increase over controls lacking L TB. and LTC •. Each 
value i~ the mean ± SD of two to eight experiments in quadruplicate. 
L~B, WIth newborn (opetl circles) or adult (solid circles) keratinocytes. LTC. 
W1th ~ewborn (opell squares) or adult (solid squares) cells. • Significant (p < 
0.01) mcrease over control at this and higher concentrations of leuko-
triene. Control (adult), 2474 ± 172 cmp; control (newborn), 1712 ± 
284 cpm. 
(Fig 1). The increases were statistically significant (p < 0.01) at 
10- 10 M (LTB4) and 10- 9 M (LTC.) and remained significant at 
higher concentrations. 
With adult keratinocytes, in contrast, LTB. and LTC. were less 
effective, showing small increases, which, although dose depen-
dent, were not significant. 
Effect ofNeuropeptides on lH_ TdR Incorporation Over the 
range from 10- 12 to 10-7 M , SP slightly increased 3H-TdR uptake 
by an insignificant amount (5-10%) in both newborn and adult 
keratinocytes; however, VIP strongly stimulated lH_ TdR uptake in 
both cell types, al.t~ough the dose ~~sponses differed markedly. 
Newborn cells exlublted a peak at 10- M, whereas the response of 
adult cells reached a plateau at 10-8 M (Fig 2). 
Synergy Between L TB. and SP or VIP When added to adult 
cells, LTB. (at a fi~ed concentration of 10- 9 M) together with SP 
(Fig 3) or VIP (Fig 4) showed synergistic increases in 3H-TdR 
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Fif're 2. ~itogenic effe~ts of SP and VIP on keratinocytes. Stimulation 
of ~-TdR mto TCA-preclpltable ~aterial. Data are expressed as percent-
age mcrease over controls lacking neuropeptides. Each value is the 
mean ± SD of three to four experiments in quadruplicate. VIP with new-
born (open circles) or adult (solid circles) cells; SP with newborn (open triatl-
gles) or adult (solid triangles) cells. • Significant (p < 0.01) increase over 
control at this and higher concentrations of neuropeptide. Control (adult), 
2582 ± 451 cpm; control (newborn), 2918 ± 811 cpm. 
134 RABIER ET AL 
100~-------------r--------------. 
--\01 








o 12 9 7 0 12 9 7 
SUBSTRNCE P (-log M) 
Figure 3. Mitogenic effects of SP and LTB, together .on keratinocytes. 
Stimulation of 3H-TdR into TCA-preapltable matenal. Data are ex-
pressed as percentage increase over controls that lacked SP and LTB,. 
Solid bars, LTB. (10- 9 M) alone; open bars, SP (10- 12 - 10- 7. M) alone; hatched 
bars, SP (10- 12 -10-7 M) plus LTB, (10- 9 M). Each value IS the mean ± SO 
of three experiments in quadruplicate .• Mean value greater than the sum 
of the means for SP and LTB, alone. Control (adult), 1918 ± 401 cpm; 
control (newborn), 2259 ± 702 cpm. 
from 10- 12 to 10- 7 M) . In the case ofLTB, plus SP, this synergy was 
appare nt at SP concentrations as low a~ 10- 9 M, and for L TB4 with 
VIP as low as 10- 9 M (for clanty, Figs 3 and 4 contam data for 
con~entrations of neuropeptides of 10-12, 10- 9 , and 10- 7 M). 
In the case of newborn cells, no synergy was observed. The in-
creases in 3H-TdR labeling occurring with SP and LTB4 were fre-
quently additive in nature . The stimulation due to VIP was usually 
comparable to that observed for VIP and L TB4 together. This held 
true no matter what concentration of VIP was used (Fig 4). 
Effects of LTC. The synergy of LTB, with SP and VIP in cul-
tures of adult cells was not observed with LTC., which was there-
fore not studied further. 
Effect of Neuropeptide Antagonists on Synergistic or Addi-
tive Behavior Between LTB. and Neuropeptides The VIP 
antagonist (10- 10 and 10- 8 !'A) ~ ~hether added to adult or to new-
born cultures, significantly mhlblted (p < 0.01) the increase in the 
3H-TdR uptake stimulated by VIP alone and by VIP added together 
with L TB4 (Fig 5). Effects were more pronounced with newborn 
cells, where the antagonist (10- 10 M) accounted for smaller in-
creases. Increases were 100% (VIP 10- 8 M) and 146% (VIP plus 
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Figure 4. Mitogenic effects of VIP and LTB, tog~ther on kerati.nocytes. 
Synergistic stimulation of 3H-TdR mto TCA-preClpltable matenal. Data 
are expressed as percentage increase over controls that lacked VIP and 
L TB,. Solid bars, LTB, (10- 9 M) alone; opetr bars, VIP (10- 12 - 10- 7 M) alone; 
hatched bars, VIP (10- 12 - 10- 7 M) plus LTB, (10- 9 M). Each value is the 
mean ± SO of three experiments in quadruplicate. • Mean value greater 
than the sum of VIP and LTB, alone. Control (adult), 1613 ± 337 cpm; 
control (newborn), 2121 ± 512 cpm. 
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Figure 5. Inhibition of VIP and VIP /LTB, mitogenicity toward keratino-
cytes by VIP antagonist. Stimulation of 3H-TdR into TCA-precipitable 
material. Data are expressed as percentage increase over controls that 
lacked any additive for adult (Ieji) and newborn (right) cells. Solid bars, 
LTB, (10- 9 M); opetr bars, VIP (10- 8 M); hatched bars, VIP (10-8 M) plus 
LTB, (10- 9 M). The VIP antagonist was added to give 10- 10 or lO- s M, as 
indicated. Each value is the mean ± SO of two experiments in quadrupli-
cate. Control (adult), 2300 ± 350 cpm; control (newborn), 2340 ± 
512 cpm. 
were only 14% and 16%, respectively. With adult cells, a similar 
amount of inhibition was observed at an antagonist concentration of 
10- 8 M . With both cell types, the effects due to L TB4 alone were 
also considerably reduced . 
Quantification of cell density by the hexosaminidase method 
using adult keratinocytes provided corroboration oPH-TdR incor-
poration data (Fig 6). Because keratinocyte growth is not sustained 
in basal media with or without neuropeptides or leukotrienes, cells 
were also cultured in a mixture of basal SFM and SFM (1: 1, vjv). 
Under these conditions, LTB4 did not affect cell growth, whereas 
VIP increased it by 76% and VIP plus LTB4 by 119%. These in-
creases were reduced to 48% and 34%, respectively, in the presence 
of the VIP antagonist at 10- 8 M. 
The inhibitory effects of spantide on the increases in 3H_ TdR 
uptake due to SP alone (10- 9 M) and due to SP and L TB4 together 
were less extensive (Fig 7). With adult cells, the synergy of SP and 
LTB4 was reduced by half when used with spantide (10-8 M). Simi-
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Figure 6. Inhibition of growth of adult keratinocytes by VIP antagonist. 
Enzyme immunoassay absorbance (mean ± SO of four wells) of adult 
keratinocytes cultured in 96-well plates for 5 d using either basal medium 
(open bars) or a mixture of basal and complete medium (1: 1 v /v, solid bars), 
either of which were supplemented as follows: (A) none; (B) LTB. 
(10- 9 M); (C) VIP (10-S M); (D) VIP + LTB, ; (E) VIP antagonist (10-S M); 
(F) VIP antagonist + VIP: (G) VIP antagonist + VIP + LTB,. 
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Figure 7. Inhibitio~ of S~ and SP / LTB,. mitogenicity ~o,:"ard kera~o­
cytes by spantide. Stimulation of 3H_ TdR mto TCA-preclpltable matenal. 
Data are expressed as percentage increase over controls that lacked any 
additive for adult (left) and newborn (right) cells. Solid bars, LTB, (10- 9 M); 
open bars, Sp (10-8 MJ; hatched bars, SP (10- 8 M) p!us LTB, (10- 9 M). ~pan­
tide was added to give 10- 10 or 10- 8 M, as mdicated. Each value IS the 
mean ± SO of two experiments in quadruplicate. Control (adult), 
2091 ± 653 cpm; control (newborn), 1638 ± 734 cpm. 
3H-TdR uptake due to L TB4 alone or SP alone. (Because stimula-
tion by SP, although invariably positive, was never found to be 
significant, the effects of spantide were difficult to evaluate). Both 
the VIP antagonist and spantide, when used by themselves, had no 
effect on 3H_ TdR uptake by either cell type. 
DISCUSSION 
SP, a tachykinin, has several properties that strongly suggest a role 
in psoriasis. It behaves as a secretagogue for mast cells (21), a mito-
gen for T cells (22) and ker~tinocytes (23), and an inducer of adhe-
sion molecules for endothehal cells and leukocytes [24). Hanley [25) 
demonstrated SP mitogenicity in psoriasis, although clearly its posi-
tive role depends on which cell type or line is selected as a model. In 
our laboratory, many experiments have demonstrated that SP gives 
rise to a marginal (10-15%) increase in 3H-TdR uptake. We were 
not able to confirm the results of Tanaka et af [23) who showed that 
SP was mitogenic to a spontaneously transformed keratinocyte cell 
line (Pam 212 cells). SP is not the only neuropeptide to show selec-
tive mitogenicity. Bombesin, for example, is mitogenic to 3T3 cells 
(26) but not to primary fibroblasts (27). Bombesin is also mitogenic 
to bronchial epithelial cells (28) but not to epidermal keratmocytes 
under our conditions (data not shown). 
Tanaka et af found that the mitogenicity of SP toward keratino-
cytes was reduced by minimizing the amount of serum in the media, 
suggesting a synergistic correlation between SP and serum growth 
factors (23). This idea is not new. When considering tachykinins as 
mitogens, Hanley suggested that they may have additive or even 
synergistic properties, or for that matter (if the neuropeptide and 
growth factor share a common mechanism as is the case with plate-
let-derived growth factor), they may show neither (25). Our study 
indicates that for the purposes of mitogenicity toward keratino-
cytes, SP does not interact with growth factors in the SFM medium 
-insulin, epidermal growth factor, and bovine pituitary extract, 
for instance. Our study does, however, demonstrate synergy of SP 
or VIP with L TB4, although it is surprising that this is seen only in 
adult cells. In newborn cells, the interactions are merely additive. 
The differences in response between newborn and adult cells are 
striking and unprecedented, at least in our experience. We do not 
know if this can be explained by differences in age of tissue or even 
by skin sites. Cells from the two sources differ not only in the nature 
and extent of their reactions to SP, VIP, and L TB" but in their 
dose-response curves as well. Newborn cells exhibit the greatest 
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response to VIP at 10- 10 M, but their response is much less at 
10-7 M. Haegerstrand et al used only a 10- 7 M concentration and 
may therefore have failed to observe the extent of the reaction to a 
lower and more physiologically significant dose (13). Adult cells, on 
the other. hand, show their highest responses at approximately 
10- 8 M Without a peak. Two classes of VIP binding sites with high 
and low affinities have been well characterized (29) on such differ-
ent cell types as human lymphocytes (kDa 0.47 nM) and intestinal 
epithelial cells (kDa 80 nM). This suggests that high-affinity VIP 
binding sites are present on newborn cells and that low-affinity sites 
are exhibited by adult cells. 
VIP is the only neuropeptide tested in our study that causes signifi-
cant increases in 3H_ TdR incorporation by keratinocytes. VIP has a 
weak mi.toge?ic effect on Swiss 3T3 murine fibroblasts in the pres-
enc~ of msulm and cAMP phosphodiesterase inhibitors (30) , sug-
gestmg that VIP uses cAMP as a second messenger. Green first 
demonstrated that cholera toxin or other agents activate the adeny-
late cycla~e of cu.ltured keratinocytes (31). cAMP may possibly medi-
ate the mltoge11lc effects of VIP shown in our study. The possibility 
that th~ effects of VIP on keratinocytes may require insulin (found 
m med1U~ SFM) led us to try the same experiment in keratinocyte 
basalm~dl~m, which lacks insulin. This control experiment gave 
results Similar to VIP 111 SFM, indicating that insulin does not ac-
count for the mitogenic effects of VIP on these cells (data not 
shown). VIP also modulates the mitogenic response of rabbit spleen 
lymphocytes r32) and has selective effects on the mitogenic re-
sponse of munne T cells (33) . The fact that SP activates the inositol 
phosphate ~essenger system (at least in mast cells) suggests that the 
cAMP-m~dlated system may be more significant for keratinocyte 
prohferatlon, because, as Our study shows, the mitogenic effects of 
VIP are far greater than those ofSp. In mast cells, however, both SP 
and VIP are secretagogues (34). 
Different observations indicate the important role that leuko-
trienes play in skin physi~logy. and i.n t1~e pathophysiology of in-
flammatory and hyperprohferatlve skill diseases. Leukotriene levels 
in interlesional skin are higher than those found in healthy skin; 
b?th, howe:rer, show levels lower than in ps~riatic lesions (35). II! 
vItro leukotnenes are known to stimulate kerat1l10cyte proliferation, 
however weakly [11). The mechanism of this action is not known. 
Muller et al (36) characterized binding sites (kDa 8.7 nM) for LTC4 (but not for LTB4) on human keratinocytes. Reusch and Wastek 
(37) des~ribed re.ceptors for LTB4 (kDa 1.03 nM). These findings 
are consistent With our Own observations that on newborn cel ls 
LTB4 has its greatest effect at 1.~ nM and that L TC4 has its greates~ 
effect at 10.0 nM. Both leukotnenes were more potent with new-
born than with adult cells, but when we observed that LTC had no 
synergy with SP on adult cells, we did not examine L TC4 any further. 
.Spantide is a well-known SP .anta~onist [38] . Because spantide 
falls to reduce the .small but POSitive ll1crease in 3H_ TdR labeling 
that we obs.erved 111 both types of keratinocytes, we suspect that 
these small.ll1crease~ may not be receptor-mediated. Spantide is, in 
fact , a partlal ag011lst (39) , which may account for its lackluster 
perform~~ce when compared with the VIP antagonist. 
In addition to suppressing the mitogenic effects due to VIP as well 
as to VIP with L TB4, the VIP antagonist reduces and, at high 
enough concentrations, eliminates the effects of L TB alone. The 
VIP ~ntagonist, which is an analogue of growtl~-hormone­
releasll1g factor, antagonizes the binding of both VIP and growth-
hormone -releasll1g factor to rat pancreatic membranes and there-
fore inh~bits the adenylate cyclase stimulation that ensues (40). The 
mecharusm by which the VIP antagonist suppresses the effects of 
L TB4 is not known. 
Proliferation of keratinocytes in psoriatic lesions may resul t not so 
much from the mitogenic effect of a single leukotriene or neuro-
peptide, but rather from the effects of a combination of the two 
different compounds acting in sy nergy. Our study showed one par-
ticular combination (VIP with L TB4) whose mitogenic effect on 
the uptake oPH-TdR was so pronounced that we expect LTB4 to 
figure prominently in our fu ture investigations into the causes of 
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psoriasis. Our studies will add.ress the interaction of neuropeptides 
with other factors (Interleukm-1a, for mstance) w h ose statu s as 
growth factors depends on the composition of their culture medium 
[41] . Neuropeptides may eventually come to be regarded as a class of 
compounds necessary for a growth factor to fully express their mi-
togenic effects . 
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